These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 33643837)

  • 1. Immune-related adverse events caused by treatment with pembrolizumab in a patient with lung cancer who infected influenza virus.
    Takemura M; Motegi M; Kuroiwa Y; Itai M; Taguchi K; Umetsu K; Uchida M; Kounoc S; Sato M; Masubuchi H; Yamaguchi A; Yamaguchi K; Ikeda K; Nakagawa J; Maeno T
    Respir Med Case Rep; 2021; 32():101361. PubMed ID: 33643837
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Isolated neutropenia as a rare but serious adverse event secondary to immune checkpoint inhibition.
    Naqash AR; Appah E; Yang LV; Muzaffar M; Marie MA; Mccallen JD; Macherla S; Liles D; Walker PR
    J Immunother Cancer; 2019 Jul; 7(1):169. PubMed ID: 31277704
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Case report: reinitiating pembrolizumab treatment after small bowel perforation.
    Beck TN; Kudinov AE; Dulaimi E; Boumber Y
    BMC Cancer; 2019 Apr; 19(1):379. PubMed ID: 31018834
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pembrolizumab combined with stereotactic body radiotherapy in a patient with human immunodeficiency virus and advanced non-small cell lung cancer: a case report.
    Li D; He C; Xia Y; Du Y; Zhang J
    J Med Case Rep; 2018 Apr; 12(1):104. PubMed ID: 29681240
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Case of Lung Adenocarcinoma with Long-Term Response after Late-Onset Pembrolizumab-Induced Acute Adrenal Insufficiency.
    Sonehara K; Tateishi K; Hirabayashi T; Araki T; Ikuyama Y; Machida R; Hanaoka M
    Case Rep Oncol; 2021; 14(1):1-7. PubMed ID: 33613234
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Case report: A rare case of neutropenia caused by pembrolizumab in squamous lung cancer and literature review.
    Tan Q; Liu L; Huang Y; Dong X; Chen L
    Front Oncol; 2022; 12():973421. PubMed ID: 36505877
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Case Report: Severe Immune-Related Cholestatic Hepatitis and Subsequent Pneumonia After Pembrolizumab Therapy in a Geriatic Patient With Metastic Gastric Cancer.
    Yang H; Zhou C; Yuan F; Guo L; Yang L; Shi Y; Zhang J
    Front Med (Lausanne); 2021; 8():719236. PubMed ID: 34712676
    [No Abstract]   [Full Text] [Related]  

  • 8. Discontinuation due to immune-related adverse events is a possible predictive factor for immune checkpoint inhibitors in patients with non-small cell lung cancer.
    Komiya K; Nakamura T; Abe T; Ogusu S; Nakashima C; Takahashi K; Kimura S; Sueoka-Aragane N
    Thorac Cancer; 2019 Sep; 10(9):1798-1804. PubMed ID: 31328416
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of Inactivated Influenza Vaccine in Cancer Patients Receiving Immune Checkpoint Inhibitors.
    Chong CR; Park VJ; Cohen B; Postow MA; Wolchok JD; Kamboj M
    Clin Infect Dis; 2020 Jan; 70(2):193-199. PubMed ID: 30874791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune checkpoint inhibitor-associated interstitial lung diseases correlate with better prognosis in patients with advanced non-small-cell lung cancer.
    Sugano T; Seike M; Saito Y; Kashiwada T; Terasaki Y; Takano N; Hisakane K; Takahashi S; Tanaka T; Takeuchi S; Miyanaga A; Minegishi Y; Noro R; Kubota K; Gemma A
    Thorac Cancer; 2020 Apr; 11(4):1052-1060. PubMed ID: 32096610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pembrolizumab-induced autoimmune encephalitis in a patient with advanced non-small cell lung cancer: A case report.
    Niki M; Nakaya A; Kurata T; Nakahama K; Yoshioka H; Kaneda T; Kibata K; Ogata M; Nomura S
    Mol Clin Oncol; 2019 Feb; 10(2):267-269. PubMed ID: 30680206
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Limb arteriolar vasculitis induced by pembrolizumab plus chemotherapy in a patient with lung cancer.
    Takada K; Hamatake M; Kohashi K; Shimamatsu S; Hirai F; Ohmori S; Tagawa T; Mori M
    Int Cancer Conf J; 2021 Jan; 10(1):83-86. PubMed ID: 33489708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Immune-related pneumonitis caused by programmed death-1 inhibitor Pembrolizumab: a case report and literature review].
    Chen YL; Zhao J; Jia R; Wang HY; Zheng J; Bai CQ; Wang MZ; Xu JM
    Zhonghua Jie He He Hu Xi Za Zhi; 2017 Oct; 40(10):736-743. PubMed ID: 29050127
    [No Abstract]   [Full Text] [Related]  

  • 14. Association of Immune-Related Adverse Events with Clinical Benefit in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Nivolumab.
    Toi Y; Sugawara S; Kawashima Y; Aiba T; Kawana S; Saito R; Tsurumi K; Suzuki K; Shimizu H; Sugisaka J; Ono H; Domeki Y; Terayama K; Nakamura A; Yamanda S; Kimura Y; Honda Y
    Oncologist; 2018 Nov; 23(11):1358-1365. PubMed ID: 29934411
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A case of meningoencephalitis associated with pembrolizumab treated for squamous cell lung cancer].
    Yonenobu Y; Ishijima M; Toyooka K; Fujimura H
    Rinsho Shinkeigaku; 2019 Feb; 59(2):105-108. PubMed ID: 30700688
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An Investigation of Nine Patients with Gastrointestinal Immune-Related Adverse Events Caused by Immune Checkpoint Inhibitors.
    Miyahara K; Noda T; Ito Y; Hidaka H; Fujimoto S; Takedomi H; Akutagawa T; Sakata Y; Shimamura T; Tominaga N; Yamaguchi D; Fujimoto K
    Digestion; 2020; 101(1):60-65. PubMed ID: 31801131
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial.
    Eggermont AMM; Kicinski M; Blank CU; Mandala M; Long GV; Atkinson V; Dalle S; Haydon A; Khattak A; Carlino MS; Sandhu S; Larkin J; Puig S; Ascierto PA; Rutkowski P; Schadendorf D; Koornstra R; Hernandez-Aya L; Di Giacomo AM; van den Eertwegh AJM; Grob JJ; Gutzmer R; Jamal R; Lorigan PC; Krepler C; Ibrahim N; Marreaud S; van Akkooi A; Robert C; Suciu S
    JAMA Oncol; 2020 Apr; 6(4):519-527. PubMed ID: 31895407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute cerebellar ataxia due to Epstein-Barr virus under administration of an immune checkpoint inhibitor.
    Saikawa H; Nagashima H; Maeda T; Maemondo M
    BMJ Case Rep; 2019 Dec; 12(12):. PubMed ID: 31892620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complete response in a patient with lung cancer suffering from three pembrolizumab-induced immune-related adverse events including retinal vasculitis.
    Mimura C; Tachihara M; Kusuhara S; Fukuoka H; Nishimura Y
    Respirol Case Rep; 2021 Apr; 9(4):e00730. PubMed ID: 33732464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute Non-infectious Cystitis Secondary to Immune-Related Adverse Events in a Patient Receiving Pembrolizumab for Treatment of Non-small Cell Lung Cancer: A Case Report.
    Alhusari L; Abdallah M; Nwanwene K; Shenouda M
    Cureus; 2024 Mar; 16(3):e55666. PubMed ID: 38586668
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.